FDA Approves New Fast-Acting Insulin

July 20, 2020

The U.S. Food and Drug Administration (FDA) has approved insulin lispro-aabc injection, 100 units/mL and 200 units/mL, a new rapid-acting insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes. Eli Lilly and Company is marketing the drug as Lyumjev™. Lyumjev is a novel formulation of insulin lispro, developed to […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

←Research Interrupted: Scientists Are Heeding the Call to Treat COVID-19 Patients

Cinnamon May Improve Blood Sugar Control in People with Prediabetes→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today